AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9840216
Drug: Marketed sustained
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed sustained release DXP‐HBr suspension
Trial: 25532503
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg)
Trial: 3598997
Drug: Nifedipine, 10
RxNorm normalized name: Nifedipine, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 10 mg sublingually
Trial: 30084233
Drug: 0.0625 mg
RxNorm normalized name: digoxin 0.0625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625 mg linaclotide
Trial: 30084233
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg linaclotide
Trial: 30084233
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg linaclotide
Trial: 30084233
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg linaclotide
Trial: 17620510
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of bone marrow-derived progenitor cells (BMCs)
Trial: 15668818
Drug: Risperidone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1 to 4 mg/day, mean dosage 1.45±0.08 mg/day)
Trial: 15668818
Drug: Risperidone (open-label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (open-label treatment after 4 weeks)
Trial: 15668818
Drug: Placebo (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (initial treatment for 4 weeks)
Trial: 11876001
Drug: Antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy (ABT) in 30-34 week neonates
Trial: 11876001
Drug: No antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibacterial therapy (ABT) in 30-34 week neonates
Trial: 11876001
Drug: Antibacterial therapy
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial therapy (ABT) in neonates < 30 weeks
Trial: 7586114
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg at 21:00 and placebo at 06:30 (150/0)
Trial: 7586114
Drug: Nizatidine 150
RxNorm normalized name: nizatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 150 mg at 21:00 and 06:30 (150/150)
Trial: 7586114
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg at 21:00 and placebo at 06:30 (300/0)
Trial: 7586114
Drug: Placebo at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at 21:00 and nizatidine 300 mg at 06:30 (0/300)
Trial: 7586114
Drug: Nizatidine 300
RxNorm normalized name: nizatidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 300 mg at 21:00 and 06:30 (300/300)
Trial: 1703655
Drug: Foreign drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foreign drug
Trial: 28131530
Drug: Vancomycin dosing
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin dosing algorithm based on estimated glomerular filtration rate from cystatin C levels (eGFRcr‐cys)
Trial: 28131530
Drug: Vancomycin dosing
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin dosing algorithm based on estimated creatinine clearance (eCLcr) using the Cockcroft‐Gault formula
Trial: 24169062
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms once daily
Trial: 9767357
Drug: n‐3 fatty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 fatty acids (4.8 g daily)
Trial: 9767357
Drug: Antioxidants (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (150 mg of vitamin C, 75 mg of vitamin E and 15 mg of beta‐carotene daily)
Trial: 8311284
Drug: Neostigmine 0.015,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.015, 0.03, 0.045, or 0.06 mg/kg
Trial: 8311284
Drug: Edrophonium 0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium 0.125, 0.25, 0.75, or 1 mg/kg
Trial: 7942250
Drug: Alcohol administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol administration
Trial: 31595608
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate 58.8 mg
Trial: 27055417
Drug: Once-daily colchicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily colchicine dosage
Trial: 27055417
Drug: Twice-daily colchicine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily colchicine dosage
Trial: 23608920
Drug: Dabrafenib administered
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib administered in nonmicronized form (larger particle size) under fasting conditions
Trial: 23608920
Drug: Dabrafenib administered
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib administered in HPMC capsules
Trial: 23608920
Drug: Dabrafenib administered
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib administered in gelatin capsules
Trial: 23608920
Drug: Dabrafenib administered
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib administered under fasting conditions
Trial: 6789008
Drug: Total Parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Parenteral Nutrition (TPN) at 35 calories/kgm/day for at least 14 days postoperatively.
Trial: 31441801
Drug: Low-dose midazolam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose midazolam
Trial: 8375835
Drug: Recent regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent regular use criteria (any past period of daily or weekly use plus any use during the 30 days before hospitalization)
Trial: 23919920
Drug: Synbiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotic mixture (two Lactobacillus strains, one Bifidobacterium strain, one Propionibacterium strain and galacto‐oligosaccharides (32 g/l))
Trial: 23921307
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg/d)
Trial: 23921307
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg/d)
Trial: 18758308
Drug: Maintenance irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance irinotecan therapy (100 mg/m IV on days 1, 8, and 15, every 4 weeks up to six cycles)
Trial: 10803042
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists and angiotensin-converting-enzyme inhibitors
Trial: 10803042
Drug: Conventional antihypertensive
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antihypertensive drugs (beta-blockers or diuretics)
Trial: 1992963
Drug: 14 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg/kg per day of oral cyclosporine for 4 weeks (Group 1)
Trial: 1992963
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg per day of oral cyclosporine for 1 to 3 months (Group 2)
Trial: 1992963
Drug: Combined data
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined data for both groups for the first 4 weeks of therapy
Trial: 25096168
Drug: Weekly paclitaxel/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly paclitaxel/carboplatin (PCw) - paclitaxel 90mg/m², cisplatin 70mg/m² or carboplatin AUC 4
Trial: 25096168
Drug: Three-weekly paclitaxel/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-weekly paclitaxel/carboplatin (PC3w) - paclitaxel 175mg/m², cisplatin 75mg/m² or carboplatin AUC 6
Trial: 21696933
Drug: E0.25 (esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0.25 (esmolol 0.25 mg/kg)
Trial: 21696933
Drug: E0.5 (esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0.5 (esmolol 0.5 mg/kg)
Trial: 21696933
Drug: E1.0 (esmolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1.0 (esmolol 1.0 mg/kg)
Trial: 19563327
Drug: IMZ implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMZ implant system (two-stage cylinder type)
Trial: 15191587
Drug: Brånemark implant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brånemark implant system (two-stage screw type)
Trial: 19563327
Drug: ITI implant
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI implant system (one-stage screw type)
Trial: 11587240
Drug: Structured care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured care outpatient treatment program
Trial: 7872284
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (1 g/day)
Trial: 2143129
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic factor (ANF) infusion at 0.25 micrograms/min
Trial: 2143129
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic factor (ANF) infusion at 2.0 micrograms/min
Trial: 332184
Drug: 4 gm
RxNorm normalized name: Olpruva 4 GM Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 gm aspirin daily for 5 days
Trial: 29342509
Drug: Combination format
RxNorm normalized name: formate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination format (numbers + IA + BS)
Trial: 18492750
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) oral (os)
Trial: 18492750
Drug: Ergocalciferol (D2)
RxNorm normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (D2) oral (os)
Trial: 18492750
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) intramuscular (im)
Trial: 18492750
Drug: Ergocalciferol (D2)
RxNorm normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (D2) intramuscular (im)
Trial: 9753533
Drug: Patient Competency
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Competency Rating Scale (PCRS) administered to TBI patients
Trial: 9753533
Drug: Patient Competency
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Competency Rating Scale (PCRS) administered to controls
Trial: 8164820
Drug: Diphenhydramine 1
RxNorm normalized name: diphenhydramine 18.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 1 mg/kg (young controls)
Trial: 3047336
Drug: Androgen priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen priming for three days before and on the day of chemotherapy
Trial: 794558
Drug: 25-hydroxycholecalciferol (25-(OH)D3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxycholecalciferol (25-(OH)D3) 25 to 50 mug/day with calcium supplementation (0.5 to 1.5 g/day)
Trial: 794558
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation alone (0.5 to 0.75 g/day)
Trial: 23561712
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg once daily for 3 days
Trial: 21364527
Drug: Cognitive‐behavioural group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioural group treatment (eight sessions)
Trial: 17374657
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (42 g)
Trial: 17374657
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (1 g)
Trial: 18772641
Drug: lumiracoxib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lumiracoxib 400 mg once daily
Trial: 15325832
Drug: ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg three times daily
Trial: 11251007
Drug: Granisetron (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (10 microg/kg IV) + Dexamethasone (20 mg PO)
Trial: 11251007
Drug: Granisetron (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (10 microg/kg IV) + MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Trial: 11251007
Drug: MK-869 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-869 (400 mg PO evening before and pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Trial: 11251007
Drug: MK-869 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-869 (400 mg PO pre-cisplatin, 300 mg PO days 2-5) + Dexamethasone (20 mg PO)
Trial: 8281644
Drug: Autonomic blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic blockade using 0.04 mg/kg atropine and 0.2 mg/kg propranolol
Trial: 2253535
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g four times a day
Trial: 2660561
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sucralfate 1 g three times a day and 400 mg cimetidine at night
Trial: 2660561
Drug: Sucralfate maintenance
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate maintenance 2 g daily
Trial: 21552054
Drug: Topical sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sucralfate (7% sucralfate ointment applied twice daily for 6 weeks)
Trial: 21552054
Drug: Placebo (petroleum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (petroleum jelly ointment applied twice daily for 6 weeks)
Trial: 21658805
Drug: Topical sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical sucralfate
Trial: 19803236
Drug: Herbal steaming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal steaming and washing therapy
Trial: 19803236
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (Vitamin B1, Vitamin B12, compound Vitamin B, small splint for wrist protection)
Trial: 18829444
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (0.625 mg/d)
Trial: 15031611
Drug: Ebastine 20
RxNorm normalized name: ebastine
DrugBank: Ebastine (DB11742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 20 mg (E20)
Trial: 12731456
Drug: Ebastine 10
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10 mg (E10)
Trial: 15160440
Drug: Loratadine 10
RxNorm normalized name: loratadine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg (L10)
Trial: 8186349
Drug: famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 40 mg b.d.
Trial: 8186349
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg b.d.
Trial: 3285836
Drug: Torasemide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (200 mg/day)
Trial: 3285836
Drug: Furosemide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (500 mg/day)
Trial: 28005003
Drug: Letter sent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letter sent from GP to parents/carers reminding about medication (n=70 practices)
Trial: 22858176
Drug: PEG‐IFN alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2a 180 μg SC
Trial: 22858176
Drug: PEG‐IFN alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2a 90 μg IV
Trial: 19324346
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) 6-g bolus IV followed by 2 g/h baseline
Trial: 12495098
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine infusion at 2 mL/hr for 48 hours plus PCA morphine
Trial: 7663867
Drug: PCA morphine
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA morphine only
Trial: 10622581
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) alone at standard dosage (3 MU t.i.w.) for 12 months
Trial: 10622581
Drug: Ribavirin as
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin as single therapy at standard dosage (15 mg/kg bodyweight in two divided doses daily)
Trial: 10622581
Drug: Ribavirin in
RxNorm normalized name: ribavirin Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin in combination with interferon alpha at standard doses for 6-12 months
Trial: 7749168
Drug: Navoban (tropisetron)
RxNorm normalized name: benzocaine / trimethobenzamide hydrochloride Rectal Suppository [Navogan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Navoban (tropisetron) monotherapy
Trial: 161170
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs in combination (IF)
Trial: 31927026
Drug: Simethicone 160
RxNorm normalized name: simethicone 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 160 mg with 50 mL water, administered 2-8 hours before surgery
Trial: 30636701
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg methylcobalamin
Trial: 30636701
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg methylcobalamin
Trial: 27281727
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL interscalene nerve block
Trial: 27281727
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL interscalene nerve block
Trial: 24679400
Drug: Venlafaxine-extended-release
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine-extended-release
Trial: 21931122
Drug: Paricalcitol (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (IV or oral depending on site)
Trial: 20032789
Drug: PCB +
RxNorm normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCB + S (25 mg daily, 2 weeks on, 1 week off)
Trial: 20032789
Drug: PCB (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCB (15 mg/kg every 3 weeks)
Trial: 12204648
Drug: Low-intensity laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity laser irradiation (HeNe, 632.8 nm) with a dose of 30 J/cm²
Trial: 10494759
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with targeted INR of 2.0 to 2.5
Trial: 10494759
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with targeted INR of 1.5 to 1.9
Trial: 8610715
Drug: Metaproterenol (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaproterenol (5% solution, 15 mg)
Trial: 1487306
Drug: Partner-specific leukocyte
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partner-specific leukocyte immunotherapy
Trial: 1487306
Drug: Own cells
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Own cells immunotherapy
Trial: 4035297
Drug: Oral water
RxNorm normalized name: Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral water
Trial: 4035297
Drug: Exogenous infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous infusions of porcine motilin (physiological and pharmacological)
Trial: 31601166
Drug: Attending 12
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attending 12 or less number of patients daily
Trial: 19589288
Drug: Nasal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation with Lavonase system (250 mL saline solution sac, twice daily for 14 days)